Results 181 to 190 of about 2,879,541 (268)

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

USPIO enhanced MR imaging in CNS tumors (UMIC): a study protocol. [PDF]

Nanomedicine (Lond)
Breese J, Lloyd W, Fothergill A, Djoukhadar I, Tyler A, Bullock E, Cloran K, Li K, Zhu X, Alfaifi B, Sereno T, Naveen Golchha P, McMahon A, Karabatsou K, D'Urso P, Maye H, Bailey M, Hannan C, King AT, Jackson A, Hinz R, Lewis D, Coope D.   +22 more
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization. [PDF]

Invest Radiol
Wessner CE, Chong W, Berreby G, Delaney LJ, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Anton K, Topper SR, Civan J, Maley W, Keith SW, Shaw CM, Eisenbrey JR.   +14 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Improving image quality in terbium-161 phantom imaging: Quantitative evaluation of DEW and TEW scatter correction methods. [PDF]

J Appl Clin Med Phys
Can M, Çapa Kaya G, Gümüşer G, Parlak Y.   +3 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Open Diagnostic Reader (ODR): An affordable, modular 3D-printed platform for standardized imaging and quantitative analysis of rapid diagnostic tests. [PDF]

HardwareX
Rogers E, Qin Z, Rahman Bhuiyan MT, Khan AI, Islam MT, Bhattacharjee P, Nabil IK, Hossain MN, Rashmi TA, Hasan M, Saha TC, Shishir SO, Washif M, Rahman MR, Mahamud I, Shahmanesh M, Hasan T, Hegde S, Qadri F, McKendry RA, Azman AS.   +20 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source